In a murine model of COPD, miR-34a inhibitors increase SIRT1 and SIRT6 expression and reduce NF-κB signaling, matrix metalloproteinase expression, cellular senescence, and emphysema severity. This evidence concerns the gene SIRT6 and chronic obstructive pulmonary disease.